MIR Stock Chart & Stats
$321.32
-$54.38(-14.47%)
At close: 4:00 PM EDT
$321.32
-$54.38(-14.47%)
Day’s Range― - ―
52-Week Range$321.32 - $562.40
Previous CloseN/A
Volume3.72K
Average Volume (3M)3.72K
Market Cap
$66.94B
Enterprise Value$5.79K
Total Cash (Recent Filing)$425.30M
Total Debt (Recent Filing)$1.23B
Price to Earnings (P/E)161.4
Beta-0.09
Next Earnings
Nov 03, 2026EPS Estimate
2.03Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)0.10
Shares Outstanding243,278,090
10 Day Avg. Volume3,720
30 Day Avg. Volume3,720
Financial Highlights & Ratios
PEG Ratio-1.05
Price to Book (P/B)2.89
Price to Sales (P/S)5.82
P/FCF Ratio50.38
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
$403.48Price Target Upside25.57% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering8
EPS Forecast (FY)9.19
Revenue Forecast (FY)$19.32B
Bulls Say, Bears Say
Bulls Say
Backlog And Nuclear DemandThe expanding backlog and strong nuclear order growth provide meaningful forward revenue visibility across installed-base, life-extension, and SMR programs. This supports demand durability and gives Mirion a foundation for sustained growth beyond a single quarter, while reducing reliance on spot sales.
Strong Cash GenerationMaterially positive operating and free cash flow strengthens Mirion’s ability to fund product development, integrate acquisitions, reduce debt, and return capital without depending entirely on external financing. Improving cash generation also provides resilience while reported profitability remains comparatively modest.
Recurring Regulated-market RevenueMirion combines product sales with recurring monitoring and service programs in nuclear, medical, and government markets where safety and compliance requirements support ongoing customer relationships. This installed-base model can encourage repeat purchases, maintenance, upgrades, and service revenue over multiple years.
Bears Say
Thin And Volatile ProfitabilityAlthough Mirion has returned to positive earnings, low current margins and a history of losses leave limited protection if demand softens, costs rise, or project execution weakens. Modest operating profitability also constrains the company’s ability to absorb volatility while funding growth initiatives.
Weak Organic Growth And Medical SoftnessThe contrast between strong consolidated growth and weak organic performance indicates that acquisitions are carrying much of the expansion burden. Medical and dosimetry weakness could limit broad-based growth, increase integration dependence, and make the underlying revenue trajectory less durable.
Project Timing And Margin PressureLarge project timing and integration-related dilution can make revenue conversion and margins uneven even with a substantial backlog. Slippage or continued acquisition costs could defer cash generation and delay expected operating leverage, increasing execution demands across the business.
MIR FAQ
What was Mirion Technologies’s price range in the past 12 months?
Mirion Technologies lowest stock price was $321.32 and its highest was $562.40 in the past 12 months.
What is Mirion Technologies’s market cap?
Mirion Technologies’s market cap is $66.94B.
When is Mirion Technologies’s upcoming earnings report date?
Mirion Technologies’s upcoming earnings report date is Nov 03, 2026 which is in 51 days.
How were Mirion Technologies’s earnings last quarter?
Mirion Technologies released its earnings results on Jul 28, 2026. The company reported $2.035 earnings per share for the quarter, beating the consensus estimate of $1.746 by $0.288.
Is Mirion Technologies overvalued?
According to Wall Street analysts Mirion Technologies’s price is currently Undervalued.
Does Mirion Technologies pay dividends?
Mirion Technologies does not currently pay dividends.
What is Mirion Technologies’s EPS estimate?
Mirion Technologies’s EPS estimate is 2.03.
How many shares outstanding does Mirion Technologies have?
Mirion Technologies has 243,278,090 shares outstanding.
What happened to Mirion Technologies’s price movement after its last earnings report?
Mirion Technologies reported an EPS of $2.035 in its last earnings report, beating expectations of $1.746. Following the earnings report the stock price went same 0%.
Which hedge fund is a major shareholder of Mirion Technologies?
Currently, no hedge funds are holding shares in MX:MIR
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Mirion Technologies Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$403.48 (25.57% Upside)
$403.48 (25.57% Upside)
Blogger Sentiment
Neutral
MX:MIR Sentiment 57%
Sector Average 59%
Sector Average 59%
Insider Transactions
Bought Shares
Worth $5.3M over
the Last 3 Months
the Last 3 Months
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-27.52%
12-Months-Change
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
28.61%
Trailing 12-Months
Learn more about TipRanks Smart Score
Company Description
Mirion Technologies
Mirion Technologies, Inc., established in 2005 and formerly known as Global Monitoring Systems, Inc. until its name change in January 2006, is based in Atlanta, Georgia. The company specializes in providing a comprehensive suite of specialized solutions for radiation detection, measurement, analysis, and monitoring. Its operations span a wide international footprint, covering countries such as the United States, Canada, the United Kingdom, France, Germany, Finland, China, Belgium, the Netherlands, Estonia, and Japan. The business is organized into two distinct operating segments: Medical and Industrial. The Medical segment delivers critical solutions aimed at enhancing patient safety and treatment accuracy within healthcare environments. Offerings here include quality assurance and dosimetry tools for radiation oncology, specialized patient safety systems for diagnostic imaging and radiation therapy centers, and precision calibration and verification solutions for medical imaging and treatment accuracy. Furthermore, it supplies radionuclide therapy products, which encompass shielding, handling equipment, dedicated medical imaging furniture, and rehabilitation aids for nuclear medicine applications. This segment fundamentally supports advancements in medical diagnostics, cancer treatment, professional safety for practitioners, and patient recovery. Conversely, the Industrial segment addresses vital requirements in radiation safety, measurement, and analysis across non-medical industries. It furnishes clients with personal radiation detection devices, identification equipment, and advanced analytical instrumentation. Mirion's extensive product and solution portfolio includes a variety of items such as nuclear medicine preparations, personal dosimeters, contamination and clearance monitoring systems, and sophisticated reactor instrumentation and control equipment. They also provide both medical and industrial imaging systems along with their related accessories, in addition to specialized instruments for alpha spectroscopy, alpha/beta counting, and gamma spectroscopy detector systems. Supplementary offerings include electrical penetration components, cancer diagnostic tools, software solutions, and a range of other services. Mirion serves a broad and varied clientele across numerous sectors. This includes healthcare providers like hospitals, clinics, urgent care facilities, dental and veterinary offices, and specialized radiation treatment centers, as well as original equipment manufacturers (OEMs) for radiation therapy. Beyond healthcare, their customers extend to research laboratories, military organizations, governmental agencies, various industrial enterprises, power and utility companies, reactor design firms, and nuclear power plants (NPPs).
MIR Company Deck
MIR Earnings Call
Q2 2026
0:00 / 0:00
Earnings Call Sentiment|Positive
The call conveyed strong operational and financial momentum driven by substantial backlog and order growth (notably in nuclear power and SMRs), expanding adjusted EBITDA margins, robust free cash flow, successful integration of Paragon, and maintained full-year guidance with good revenue coverage. Offsetting risks include weak organic revenue (medical softness and dosimetry declines), an $18M China debooking, M&A-related margin dilution, and timing/execution risk on large opportunities. On balance the positive drivers (backlog growth, margin expansion, cash generation, large wins, AI/product innovation) materially outweigh the near-term challenges, supporting constructive outlook for the remainder of 2026.View all MX:MIR earnings summariesMIR Stock 12 Month Forecast
All Analysts
Top Analysts
Average Price Target
$403.48
▲(25.57% Upside)
Technical Analysis
1 Day
3 Days
1 Week
1 Month








